← Retour au blog
tech 24 August 2026

FDA Approves Blood Test for Alzheimer's Disease Evaluation

The FDA has approved the PrecivityAD2 blood test, a significant breakthrough in early Alzheimer's disease diagnosis. Developed by WashU, this test uses mass spectrometry to detect amyloid plaques with over 90% accuracy.

Article inspired by the original source
FDA clears blood test to aid evaluation for Alzheimer's disease ↗ medicine.washu.edu

A Step Forward in Alzheimer's Diagnosis

Alzheimer’s disease, a scourge affecting millions worldwide, might soon be easier to detect thanks to a new technological breakthrough. The U.S. Food and Drug Administration (FDA) has recently approved a blood test, PrecivityAD2, which could revolutionize the diagnosis of this devastating disease.

The Technology Behind PrecivityAD2

Developed by C2N Diagnostics, a startup from Washington University in St. Louis, the PrecivityAD2 test is based on high-resolution mass spectrometry technology. Unlike traditional methods requiring spinal taps or costly brain scans, this test offers a less invasive and more accessible alternative.

The test detects specific biomarkers, notably amyloid plaques, associated with Alzheimer's disease. With over 90% accuracy, it provides clinicians with a new method to evaluate the presence of these plaques in certain patients.

Implications for the Medical Sector

The FDA's approval of this test marks a turning point in how Alzheimer's disease is diagnosed. According to a report by the Alzheimer's Association, approximately 6.2 million Americans aged 65 and older are living with this disease. The costs associated with care for these patients are expected to reach $355 billion in 2021, with forecasts for increases in the coming years.

With PrecivityAD2, doctors can not only diagnose the disease earlier but also potentially reduce care costs by enabling faster and more targeted treatment. Moreover, this approach could encourage the development of new therapies and improve clinical trial outcomes by allowing more precise participant selection.

A Promising Future

The introduction of this test could also have broader implications for research on other neurodegenerative diseases. By making diagnosis more accessible, it paves the way for a better understanding of the underlying mechanisms of these diseases and the discovery of new treatments.

Conclusion

The PrecivityAD2 blood test represents a significant advance in the fight against Alzheimer's disease. By reducing reliance on invasive procedures and offering a more affordable solution, it is a game-changer for patients and healthcare professionals. Its adoption could not only improve diagnoses but also transform the overall approach to care.

Let's discuss your project in 15 minutes.

Alzheimer diagnostic biomarqueurs spectrométrie de masse FDA
Deepthix newsletter · 100% AI · every Monday 8am

An AI agent reads tech for you.

Our AI agent scans ~200 sources per week and ships the best articles to your inbox Monday 8am. Free. One click to unsubscribe.

Visit the newsletter page →

Want to automate your operations?

Let's talk about your project in 15 minutes.

Book a call